Recursion Announces First Internally-Developed NCE Advanced

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis


Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion's ML-enabled Operating System for the potential treatment of C. difficile.

Related Keywords

Chris Gibson , Elyse Freeman , Exchange Commission , Recursion Pharmaceuticals Inc , Nasdaq , Recursion Pharmaceuticals , New Chemical Entity , Recursion Operating System , Operating System , Recursion Map , Securities Litigation Reform Act , கிறிஸ் கிப்சன் , பரிமாற்றம் தரகு , நாஸ்டாக் , புதியது இரசாயன நிறுவனம் , இயங்குகிறது அமைப்பு , பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

© 2025 Vimarsana